Urgent Evaluation and Biopsy of Suspected Melanoma

Clinical Features Indicative of Melanoma

• Recent change in size and color (evolution) is the most critical warning sign for melanoma. National Comprehensive Cancer Network (NCCN) guidelines emphasize this as a key diagnostic cue. 1
• A brown, raised, rough‑textured lesion suggests a nodular or thick melanoma subtype. NCCN highlights texture changes as concerning. 1
• Lesions located on the lower back are a common site for melanoma in women, reinforcing the need for heightened suspicion in this region. British Association of Dermatologists (as reported in British Journal of Dermatology) note this distribution pattern. 2

Urgent Referral and Timing

• Patients with suspicious pigmented lesions should be referred immediately to a dermatologist or surgeon/plastic surgeon experienced in pigmented lesions, with systems guaranteeing the patient is seen within 2 weeks of referral receipt. British Association of Dermatologists recommendation. 2
• Referral documentation must list the specific concerning features (e.g., recent darkening, enlargement, pruritus, raised/rough texture), the exact anatomical location, and the approximate size of the lesion. British Association of Dermatologists guidance. 2

Biopsy Technique Recommendations (Specialist Only)

• Full‑thickness elliptical excisional biopsy is required, encompassing the entire lesion with a 2–5 mm clinical margin of normal skin laterally and a cuff of subcutaneous fat deep to the lesion. British Association of Dermatologists protocol. 2
• The specimen should be oriented for potential re‑excision (longitudinal orientation on extremities or along skin tension lines). NCCN recommendation. 3
• Preserve lymphatic drainage patterns during excision to allow for future sentinel lymph node biopsy if indicated. NCCN recommendation. 3

Procedures to Avoid in Primary Care

• Shave biopsy – precludes accurate pathological staging and should not be performed. British Association of Dermatologists and NCCN advise against it. [2][3]
• Punch biopsy – prevents reliable Breslow thickness measurement and carries a risk of sampling error. British Association of Dermatologists guidance. 2
• Incisional biopsy – inadequate for staging and not recommended. British Association of Dermatologists and NCCN advise against it. [2][3]
• Attempted excision without proper training – full‑thickness technique including subcutaneous fat is essential; untrained attempts risk understaging. British Association of Dermatologists recommendation. 2

Pathology Reporting Requirements

• Breslow thickness (mm) – the single most important prognostic factor. NCCN mandates its measurement. [1][3]
• Ulceration status (present or absent) – critical for staging. NCCN requires reporting. [1][3]
• Mitotic rate (mitoses per mm²) – an independent prognostic indicator. NCCN includes this in the pathology checklist. [1][3]
• Clark level of invasion – especially relevant for thin melanomas. NCCN recommends documentation. 3

Management After Histopathologic Confirmation

• Wide local excision with margins based on Breslow thickness:
  
  • 1 cm margin for ≤1 mm thickness
  • 1–2 cm margin for 1.01–2 mm thickness
  • 2 cm margin for >2 mm thickness. NCCN margin guidelines. 3
• Sentinel lymph node biopsy should be considered for lesions >0.8–1.0 mm thick or those with high‑risk features (e.g., ulceration, high mitotic rate). NCCN recommendation. [1][3]
• Annual full‑body skin examinations for life are advised because the risk of a second primary melanoma is significantly elevated. American Academy of Dermatology (AAD) guideline. 4
• Patient education on self‑examination techniques and sun‑protection measures is essential for secondary prevention. AAD and British Association of Dermatologists guidance. [4][2]

Evaluation and Management of Suspicious Skin Lesions

Initial Clinical Assessment

• The American Joint Committee on Cancer recommends the ABCDE schema for evaluating pigmented lesions, which includes Asymmetry, Border irregularity, Color heterogeneity, Diameter, and Evolution 5, 6
• Complete skin examination is mandatory for all patients presenting with a suspicious lesion, and should include full body skin surface inspection, regional lymph node palpation, abdominal examination, and documentation of lesion site, size, and characteristics 7, 8, 9, 10

Risk Stratification for Basal Cell Carcinoma

• Location and size are critical risk factors for BCC recurrence, with high-risk locations including the "H-zone" or mask areas of the face, head and neck region, and high-risk size thresholds including ≥6 mm in high-risk facial locations and ≥10 mm in moderate-risk locations 9, 10
• The National Comprehensive Cancer Network recommends considering additional high-risk features, such as deep soft tissue involvement, bone involvement, and perineural invasion, when assessing BCC risk 9, 10

Biopsy Technique Requirements

• The British Journal of Dermatology recommends full-thickness excisional biopsy as the only acceptable approach for suspected melanoma, with a 2-5 mm clinical margin of normal skin laterally and a cuff of subdermal fat to allow accurate Breslow thickness measurement 7, 8, 11
• The Journal of the National Comprehensive Cancer Network recommends that biopsy must include deep reticular dermis when the lesion appears more than superficial for suspected basal cell carcinoma 9, 10

Urgent Referral Criteria

• Patients with melanoma-suspicious lesions require urgent specialist referral to a dermatologist or surgeon with expertise in pigmented lesions, with systems ensuring evaluation within 2 weeks of referral 7, 8, 11

Histopathology Requirements

• The pathology report must include Breslow thickness in millimeters, Clark level of invasion, presence and extent of ulceration, presence and extent of regression, surgical margin clearance status, and histological type and special variants 7, 12, 6
• The Annals of Oncology recommends processing by an experienced pathology institute following WHO classification 12, 6

Common Pitfalls to Avoid

• The British Journal of Dermatology recommends maintaining a low threshold for biopsy in high-risk populations, such as those with prior skin cancer, immunosuppression, or genetic syndromes 9, 10

High-Risk Patient Surveillance

• Patients with prior melanoma or atypical mole syndrome require education on melanoma recognition and monthly self-examination, and patients with giant congenital pigmented nevi require long-term follow-up due to increased melanoma risk 7, 8, 11
• Genetic counseling referral is indicated for families with three or more melanoma cases, or two cases if one had multiple primaries or atypical mole syndrome 7, 8, 11

Guideline Recommendations for Diagnosis and Management of Skin Cancer

Diagnostic Approach

• The American Academy of Dermatology recommends using the ABCDE criteria (Asymmetry, Border irregularity, Color heterogeneity, Diameter > 6 mm—note that 38 % of melanomas are ≤6 mm, and Evolution) to identify suspicious pigmented lesions. 13, 14
• Dermoscopy performed by experienced clinicians improves diagnostic accuracy for both melanoma and keratinocyte carcinomas compared with naked‑eye examination. 13, 15, 16

Biopsy Technique for Suspected Melanoma

• An urgent full‑thickness elliptical excisional biopsy with 2–5 mm lateral margins of normal skin and a cuff of subcutaneous fat is mandatory; shave, punch, or incisional biopsies must be avoided because they prevent accurate Breslow thickness measurement and can lead to understaging. 13

Pathology Reporting Requirements

• All the above elements should be reported in the pathology report for melanoma. 13, 15, 16

Treatment of Primary Melanoma

• Wide local excision margins are based on Breslow thickness:

• Sentinel lymph node biopsy (SLNB) is indicated for lesions >0.8–1.0 mm thick or those with high‑risk features (ulceration, high mitotic rate); SLNB provides accurate staging but has not shown an overall survival benefit. It should be performed only by experienced multidisciplinary teams. 15, 16

Management of Melanoma In Situ (Lentigo Maligna Type)

• Surgical excision remains the first‑line therapy. 13
• Mohs micrographic surgery may be selected for cosmetically or functionally sensitive sites. 13
• Topical imiquimod 5 % cream can be used as primary or adjuvant treatment (apply five times weekly for six weeks, leaving on skin ~8 h before washing). 13
• Radiation therapy is an alternative for patients who are not surgical candidates. 13

Basal Cell Carcinoma (BCC)

• Surgical excision with risk‑adjusted margins is recommended for most BCCs. 14
• Mohs micrographic surgery is preferred for high‑risk lesions or those in cosmetically sensitive areas. 14
• Radiation therapy, electrodesiccation and curettage, or photodynamic therapy may be employed for selected cases. 14

Squamous Cell Carcinoma (SCC)

• Surgical excision is the primary treatment modality. 14
• Mohs micrographic surgery is advised for high‑risk SCCs. 14
• Radiation therapy can be used as primary or adjuvant therapy when surgery is contraindicated or as part of multimodal management. 14

Critical Pitfalls to Avoid

• Performing shave or punch biopsies on lesions suspected to be melanoma is the most common error and compromises accurate staging. 13

Screening and Surveillance

• Routine whole‑body skin‑examination screening of asymptomatic average‑risk adults lacks sufficient evidence to demonstrate a mortality or morbidity benefit. 17, 18, 19, 14
• Primary‑care physicians achieve moderate diagnostic accuracy for melanoma (sensitivity 42–100 %, specificity 70–98 %) when using image‑based assessments rather than full‑body examinations. 17, 18, 19, 20
• Screening programs tend to detect thinner melanomas compared with usual care, but it remains unproven whether this translates into reduced mortality. 17, 18, 19, 20